Freenome is a biotech company developing accurate, accessible, and non-invasive disease screening products for proactively treating cancer and other diseases at their most manageable stages. The company is developing a simple blood test to detect early-stage cancer and make treatments more effective and provides a platform that helps design healthy conditions for an individual based on his/her cell-free genome. The company aims to reinvent disease management through systematized early detection and intervention. Charles Roberts, Gabriel Otte, Riley Ennis, and Michael Otte launched the company in 2014 in South San Francisco, California.

Freenome's core mission is centered around revolutionizing the early detection and treatment of cancer through the power of artificial intelligence and advanced genomics. By developing non-invasive blood tests, Freenome aims to identify cancer at its earliest stages, enabling more effective interventions and improving patient outcomes. Through their innovative technology and multidisciplinary approach, Freenome is dedicated to transforming the healthcare landscape and saving lives by making early cancer detection accessible and reliable for all.

• Competitive base salary
• Pre-IPO equity
• Cash bonuses
• Full range of medical benefits
• Financial benefits
• Other benefits depending on the position offered

• Innovation: Freenome values innovation and encourages employees to think outside the box to drive progress in the field of early cancer detection.
• Collaboration: Collaboration is key at Freenome, where teamwork and open communication are essential to achieving their mission.
• Diversity & Inclusion: Freenome is committed to creating an inclusive workplace that values diversity and promotes equity for all employees.
• Integrity: Freenome operates with integrity, maintaining the highest ethical standards in all aspects of their work.